- Romania
- /
- Basic Materials
- /
- BVB:HEAL
S.C. Helios S.A. (BVB:HEAL) Stock Rockets 192% But Many Are Still Ignoring The Company
S.C. Helios S.A. (BVB:HEAL) shareholders would be excited to see that the share price has had a great month, posting a 192% gain and recovering from prior weakness. Longer-term shareholders would be thankful for the recovery in the share price since it's now virtually flat for the year after the recent bounce.
In spite of the firm bounce in price, S.C. Helios' price-to-earnings (or "P/E") ratio of 9.9x might still make it look like a buy right now compared to the market in Romania, where around half of the companies have P/E ratios above 15x and even P/E's above 39x are quite common. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's limited.
S.C. Helios certainly has been doing a great job lately as it's been growing earnings at a really rapid pace. It might be that many expect the strong earnings performance to degrade substantially, which has repressed the P/E. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.
View our latest analysis for S.C. Helios
We don't have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our free report on S.C. Helios' earnings, revenue and cash flow.Is There Any Growth For S.C. Helios?
There's an inherent assumption that a company should underperform the market for P/E ratios like S.C. Helios' to be considered reasonable.
Retrospectively, the last year delivered an exceptional 35% gain to the company's bottom line. The latest three year period has also seen an excellent 53% overall rise in EPS, aided by its short-term performance. So we can start by confirming that the company has done a great job of growing earnings over that time.
Weighing the recent medium-term upward earnings trajectory against the broader market's one-year forecast for contraction of 6.4% shows it's a great look while it lasts.
With this information, we find it very odd that S.C. Helios is trading at a P/E lower than the market. It looks like most investors are not convinced at all that the company can maintain its recent positive growth rate in the face of a shrinking broader market.
The Final Word
S.C. Helios' stock might have been given a solid boost, but its P/E certainly hasn't reached any great heights. It's argued the price-to-earnings ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.
Our examination of S.C. Helios revealed its growing earnings over the medium-term aren't contributing to its P/E anywhere near as much as we would have predicted, given the market is set to shrink. We think potential risks might be placing significant pressure on the P/E ratio and share price. Perhaps there is some hesitation about the company's ability to stay its recent course and swim against the current of the broader market turmoil. At least the risk of a price drop looks to be subdued, but investors think future earnings could see a lot of volatility.
It's always necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with S.C. Helios, and understanding them should be part of your investment process.
Of course, you might also be able to find a better stock than S.C. Helios. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BVB:HEAL
S.C. Helios
Engages in the fabrication of refractory materials in Romania.
Flawless balance sheet with solid track record.